CD3 (CD3E / CD3 epsilon) is a core component of the T-cell receptor (TCR) signaling complex and one of the most widely used markers for T-cell identification. As the universal binding arm for bispecific T-cell engagers (BiTEs), CAR-T constructs, and T-cell-redirecting immunotherapies, CD3 reagents are essential in both basic immunology and therapeutic antibody development. abinScience offers a comprehensive CD3 portfolio including recombinant CD3 proteins, anti-CD3 monoclonal antibodies, biosimilar reference standards, and ELISA kits.
The CD3 complex consists of four subunits — CD3 epsilon (CD3E), CD3 delta, CD3 gamma, and CD3 zeta — that associate with the TCR alpha/beta heterodimer to form the complete TCR–CD3 complex. CD3E is the most therapeutically relevant subunit because it is exposed on the T-cell surface and serves as the primary docking site for T-cell-engaging bispecific antibodies.
Upon antigen recognition, the CD3 complex transmits activation signals through its intracellular immunoreceptor tyrosine-based activation motifs (ITAMs), triggering T-cell proliferation, cytokine release, and cytotoxic activity. This central role in T-cell activation makes CD3 a critical target in immuno-oncology, transplant immunology, and autoimmune disease research.
| Application | Recommended Product Type | Format |
|---|---|---|
| SPR/BLI binding kinetics | Recombinant CD3E protein | Avi-tagged or biotinylated |
| Bispecific bridging ELISA | Recombinant CD3E protein | His-tagged or Fc-chimera |
| T-cell activation / proliferation | Anti-CD3 antibody (OKT3 clone) | Unconjugated, low endotoxin |
| Flow cytometry / FACS | Anti-CD3 antibody | FITC, PE, APC, or PerCP conjugated |
| WB / IHC detection | Anti-CD3E polyclonal or monoclonal antibody | Unconjugated |
| PK/ADA ELISA | Matched antibody pair + calibrator protein | Capture/detection pair |
| Comparability / reference | Anti-CD3 biosimilar (Muromonab analog) | Research-grade RUO |
1. Birkinshaw RW, et al. (2024) Structure and function of the T cell receptor–CD3 complex. Nat Rev Immunol. DOI: 10.1038/s41577-024-01094-w
2. Labrijn AF, et al. (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 18(8):585-608. PMID: 31175342
3. Goebeler ME, Bargou RC. (2020) T cell-engaging therapies — BiTEs and beyond. Nat Rev Clin Oncol. 17(7):418-434. PMID: 32132672
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa-lambda
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-Kappa
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa/scFv-h-CH2-CH3
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
Ig(G4-kappa_G4-lambda)
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa/lambdawithdomaincrossover
Mammalian cells
P07766
Met1-Asp126
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Homo sapiens (Human)
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Chimeric
Ig(G1-kappa_G1-lambda)
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Chimeric
IgG4-lambda